Morphic Holding, Inc. is a biopharmaceutical company dedicated to the discovery and advancement of oral, small-molecule integrin-based therapies. These treatments are designed to address a broad spectrum of conditions, including autoimmune, cardiovascular, and metabolic diseases, as well as various forms of fibrosis and cancer. The company's principal therapeutic candidates include MORF-057, an a4ß7-specific integrin inhibitor targeting inflammation, currently undergoing Phase 1 clinical trials for inflammatory bowel disease and in preclinical development for idiopathic pulmonary fibrosis and other fibrotic ailments.